news
12 July 2020
Les Echos : Comment la biotech Da Volterra veut combattre la résistance aux antibiotiques
La biotech a mis au point un adsorbant intestinal qui capte les résidus d’antibiotiques évitant ainsi la sélection de bactéries…
Our vision
A HEALTHY MICROBIOTA
Da Volterra is a clinical stage biotechnology company whose vision is to be a trusted and acknowledged leader in the microbiota field.
Our mission is to discover, develop and bring to market safe and novel therapeutic options, preserving patients’ microbiota to prevent and cure life-threatening diseases.
We strive to serve patients by transforming the promise of science into innovative treatments which have the power to improve health and save lives.
Our most advanced product
DAV132
DAV132 is a novel colon-targeted adsorbent developed to prevent antibiotic-induced dysbiosis. It has already undergone multiple clinical trials, including a multicenter phase 2 study in Europe. It has been developed using in-house expertise on gut microbiota, drug delivery technologies and antibiotics.